Notice of Intent to Sole Source – Agilent Technologies
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The National Institutes of Health (NIH) intends to award a fixed-price purchase order on a sole source basis to Agilent Technologies for reagents and preventative maintenance for the Seahorse XFEe Analyzer at the NIH Clinical Center. This is a Notice of Intent, not a request for quotation. Interested parties may submit capabilities by May 4, 2026, at 2 PM EST.
Scope of Work
This acquisition covers:
- Provision of reagents and kits for the Seahorse XFEe Analyzer.
- Preventative maintenance services for the Seahorse XFEe Analyzer.
The equipment is crucial for measuring cellular potency using metabolic activity, particularly for CAR T cell and other cell product manufacturing, and is required for the release of cellular therapy products. The preventative maintenance ensures compliance with manufacturer guidelines and FDA 21 CFR 211.67.
Contract & Timeline
- Type: Notice of Intent to Sole Source (Fixed-Price Purchase Order)
- Proposed Vendor: Agilent Technologies
- Set-Aside: Sole Source (FAR Part 13 – Simplified Acquisition Procedures)
- Response Due: May 4, 2026, 2 PM EST
- Published: April 27, 2026
- Place of Performance: Bethesda, MD 20892 USA
- Product Service Code: 6515 – Medical Instruments, Equipment, and Supplies
- NAICS Code: 339112 – Surgical and Medical Instrument Manufacturing
Evaluation
The NIH intends to award this contract to Agilent Technologies based on a sole source determination under FAR Part 13.106-1(b)(1). Agilent Technologies is identified as the sole vendor providing the clinically approved platform for reagents, kits, and instruments, and is the only provider of periodic preventative maintenance for the Seahorse XFe96 device.
Additional Notes
This notice is for informational purposes only; a solicitation will not be issued. Interested parties who believe they can meet this requirement may submit a statement of capabilities to Kristin Nagashima at Kristin.nagashima@nih.gov. The government's decision not to compete this requirement is at its sole discretion.